Holen Sie sich die Stockscreener-App
4.35
0.69%
0.03
Handel nachbörslich:
4.43
0.08
+1.84%
Schlusskurs vom Vortag:
$4.32
Offen:
$4.36
24-Stunden-Volumen:
1.12M
Relative Volume:
2.07
Marktkapitalisierung:
$257.04M
Einnahmen:
$192.64M
Nettoeinkommen (Verlust:
$2.51M
KGV:
83.02
EPS:
0.0524
Netto-Cashflow:
$12.42M
1W Leistung:
-20.91%
1M Leistung:
-12.83%
6M Leistung:
-3.55%
1J Leistung:
-6.45%
1-Tages-Spanne:
$4.28
$4.51
1-Wochen-Bereich:
$4.28
$5.70
52-Wochen-Spanne:
$3.8092
$5.70
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Firmenname
Vanda Pharmaceuticals Inc
Sektor
Branche
Telefon
202-734-3400
Adresse
2200 PENNSYLVANIA AVE NW, WASHINGTON
Vergleichen Sie VNDA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
4.35 | 255.27M | 192.64M | 2.51M | 12.42M | 0.0524 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-31 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-02-25 | Herabstufung | Jefferies | Buy → Hold |
| 2021-05-12 | Eingeleitet | BofA Securities | Buy |
| 2021-01-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-06-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-03-16 | Herabstufung | Oppenheimer | Perform → Underperform |
| 2020-03-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-11-07 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-08-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-07-25 | Herabstufung | Stifel | Buy → Hold |
| 2018-12-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2018-12-04 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | Bestätigt | Jefferies | Buy |
| 2018-11-08 | Fortgesetzt | Jefferies | Buy |
| 2018-09-21 | Fortgesetzt | Oppenheimer | Outperform |
| 2018-05-23 | Eingeleitet | Citigroup | Buy |
| 2018-01-19 | Eingeleitet | Seaport Global Securities | Buy |
| 2017-09-14 | Bestätigt | Piper Jaffray | Overweight |
| 2017-06-27 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-05-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-04-12 | Eingeleitet | Oppenheimer | Outperform |
| 2016-11-09 | Eingeleitet | Aegis Capital | Buy |
| 2016-10-06 | Fortgesetzt | Jefferies | Buy |
Alle ansehen
Vanda Pharmaceuticals Inc Aktie (VNDA) Neueste Nachrichten
FY2025 EPS Estimates for VNDA Boosted by Cantor Fitzgerald - MarketBeat
Can Vanda Pharmaceuticals Inc. stock deliver surprise earnings beat2025 Stock Rankings & Weekly Watchlist of Top Performers - newser.com
Backtesting results for Vanda Pharmaceuticals Inc. trading strategiesJuly 2025 Drop Watch & Fast Entry High Yield Stock Tips - newser.com
Assessing Vanda Pharmaceuticals (VNDA) Valuation After Q3 2025 Growth and Updated FDA Milestones - Yahoo Finance
Visualizing Vanda Pharmaceuticals Inc. stock with heatmapsMarket Activity Report & Daily Profit Maximizing Trade Tips - newser.com
Is Vanda Pharmaceuticals Inc. stock safe for conservative investorsMarket Trend Report & Fast Moving Stock Trade Plans - newser.com
How institutional buying supports Vanda Pharmaceuticals Inc. stock2025 Top Decliners & Smart Swing Trading Techniques - newser.com
News impact scoring models applied to Vanda Pharmaceuticals Inc.July 2025 Recap & Free Daily Entry Point Trade Alerts - newser.com
Vanda Pharmaceuticals (NASDAQ:VNDA) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Vanda Pharmaceuticals Reports Strong Sales Growth and Pipeline Progress - MSN
Cantor Fitzgerald Cuts Vanda Pharmaceuticals (NASDAQ:VNDA) Price Target to $11.00 - MarketBeat
Jim Cramer on Vanda Pharmaceuticals: “I’m Going to Bless That One as Your Spec” - MSN
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q3 2025 Earnings Call Transcript - Insider Monkey
Vanda Pharmaceuticals Q3 Earnings Preview - MSN
Published on: 2025-10-31 05:46:53 - newser.com
Applying big data sentiment scoring on Vanda Pharmaceuticals Inc.2025 Growth vs Value & Low Risk Profit Maximizing Plans - newser.com
Real time pattern detection on Vanda Pharmaceuticals Inc. stockQuarterly Profit Review & Consistent Return Strategy Ideas - newser.com
Vanda Pharmaceuticals Inc. stock retracement – recovery analysis - newser.com
Will Vanda Pharmaceuticals Inc. stock recover after recent dropShare Buyback & Weekly Watchlist for Consistent Profits - newser.com
Can Vanda Pharmaceuticals Inc. recover in the next quarterWeekly Investment Report & Reliable Entry Point Alerts - newser.com
Will Vanda Pharmaceuticals Inc. (VM4) stock remain on Wall Street radarExit Point & Momentum Based Trading Ideas - newser.com
Is Vanda Pharmaceuticals Inc. (VM4) stock considered safe havenBond Market & AI Driven Price Forecasts - newser.com
Smart tools for monitoring Vanda Pharmaceuticals Inc.’s price actionWeekly Gains Summary & Scalable Portfolio Growth Methods - newser.com
How Vanda Pharmaceuticals Inc. stock performs in interest rate cyclesMarket Volume Report & High Win Rate Trade Alerts - newser.com
How supply shortages influence Vanda Pharmaceuticals Inc. (VM4) stock2025 Top Gainers & Verified Entry Point Signals - newser.com
Vanda Pharmaceuticals (VNDA): Forecasts See Earnings Growth of 68.5% Annually Heading Into Earnings Season - Sahm
Vanda Pharmaceuticals (VNDA): Revenue Projected to Grow 22.7% Annually, Profitability in Focus Ahead of Earnings - Yahoo Finance
Vanda Pharmaceuticals Inc (VNDA) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... By GuruFocus - Investing.com Canada
Vanda Pharmaceuticals Inc. (VNDA) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Vanda Pharmaceuticals (NASDAQ:VNDA) Posts Quarterly Earnings Results, Hits Estimates - MarketBeat
Vanda Pharmaceuticals Inc (VNDA) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising Expenses - GuruFocus
VNDA Analyst Rating Update: Cantor Fitzgerald Adjusts Price Target | VNDA Stock News - GuruFocus
Vanda Pharmaceuticals Inc. SEC 10-Q Report - TradingView
Vanda Sees Sales Jump, But Losses Also Pile Up - Finimize
Vanda: Q3 Earnings Snapshot - CT Insider
Vanda Pharmaceuticals Q3 2025 Earnings Call Transcript - MarketBeat
Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Vanda Pharmaceuticals Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Vanda Pharmaceuticals Q3 2025 Earnings: EPS of -$0.38 Beats Esti - GuruFocus
Vanda Pharmaceuticals Q3 2025 Earnings: EPS of -$0.38 Beats Estimates, Revenue of $56.3M Misses Expectations - GuruFocus
Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results - Lelezard
Finanzdaten der Vanda Pharmaceuticals Inc-Aktie (VNDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.62%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):